艾迪注射液联合化疗治疗晚期非小细胞肺癌的疗效及安全性分析

Efficacy and safety of Aidi injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer

目的探讨晚期非小细胞肺癌患者采用常规化疗联合艾迪注射液治疗的临床疗效及安全性。方法89例晚期非小细胞肺癌患者,采用随机数字法分为实验组(44例)和对照组(45例)。对照组患者采用常规化疗方案进行治疗,实验组患者给予艾迪注射液联合常规化疗方案进行治疗。比较两组患者治疗前后的生活质量评分,治疗后的临床疗效,治疗前后的免疫指标[免疫球蛋白M(IgM)、免疫球蛋白A(IgA)、免疫球蛋白G(IgG)]水平,不良反应发生情况。结果治疗后,实验组患者的生活质量评分(78.72±16.52)分高于对照组的(67.24±15.63)分,差异具有统计学意义(P<0.05)。实验组患者的总缓解率为36.4%,与对照组的22.2%比较,差异无统计学意义(P>0.05);实组患者的疾病控制率为88.6%,高于对照组的71.1%,差异具有统计学意义(P<0.05)。治疗后,两组患者的IgM、IgA、IgG水平均低于本组治疗前,但实验组患者的IgM(0.63±0.01)g/L、IgA(1.18±0.05)g/L、IgG(9.87±1.10)g/L均高于对照组的(0.29±0.04)、(1.14±0.06)、(8.71±0.92)g/L,差异具有统计学意义(P<0.05)。实验组患者的呕吐、白细胞减少、乏力发生率分别为4.5%、6.8%、11.4%,均低于对照组的26.7%、24.4%、28.9%,差异具有统计学意义(P<0.05)。结论化疗联合艾迪注射液治疗晚期非小细胞肺癌,能提高患者的生存质量,并缓解患者治疗后的不良反应,提高治疗安全性。

Objective To discuss the clinical efficacy and safety of Aidi injection combined with chemotherapy in the treatment of advanced non-small cell lung cancer.Methods A total of 89 patients with advanced non-small cell lung cancer were divided into an experimental group(44 cases)and a control group(45 cases)according to the random numerical table.The control group was treated with conventional chemotherapy,and the experimental group was treated with Aidi injection and conventional chemotherapy.Both groups were compared in terms of quality of life scores before and after treatment,the clinical efficacy after treatment,the levels of immune indexes[immunoglobulin M(IgM),immunoglobulin A(IgA),immunoglobulin G(IgG)]before and after treatment,and the occurrence of adverse reactions.Results After treatment,the quality of life score of(78.72±16.52)points in the experimental group was higher than that of(67.24±15.63)points in the control group,and the difference was statistically significant(P<0.05).The total remission rate in the experimental group was 36.4%,and the difference was not statistically significant when compared with that of 22.2%in the control group(P>0.05).The disease control rate in the experimental group was 88.6%,which was higher than that of 71.1%in the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of IgM,IgA and IgG in both groups were lower than those before treatment in this group;however,IgM of(0.63±0.01)g/L,IgA of(1.18±0.05)g/L and IgG of(9.87±1.10)g/L in the experimental group were higher than those of(0.29±0.04),(1.14±0.06)and(8.71±0.92)g/L in the control group.The differences were statistically significant(P<0.05).The incidence of vomiting,leukopenia and fatigue in the experimental group were 4.5%,6.8%and 11.4%,which were lower than those of 26.7%,24.4%and 28.9%in the control group,and the differences were statistically significant(P<0.05).Conclusion Chemotherapy combined with Aidi injection in the treatment of advanced non-small cell lung cancer can improve the quality of life of patients,alleviate the adverse reactions after treatment,and improve the safety of treatment.